VolitionRX (VNRX) Registration Filing summary

Company overview and business model

• Multi-national epigenetics company with patented technologies using chromosomal structures and transcription factors as biomarkers for cancer and other diseases.

• Product portfolio includes tests for early detection and monitoring of diseases such as cancer, sepsis, and COVID-19.

• Key product pillars: Nu.Q® Vet (canine cancer screening), Nu.Q® NETS (immune monitoring), Nu.Q® Discover (nucleosome profiling), Nu.Q® Cancer (disease monitoring), and Capture-PCR™ (early cancer detection via tumor DNA isolation).

• Operations span Belgium, California, London, Singapore, and Nevada, with significant lab and production facilities.

Financial performance and metrics

• As of November 7, 2024, 92,664,812 shares of common stock outstanding; last reported sale price was $0.6579 per share on NYSE American.

• Classified as a smaller reporting company, providing less public disclosure than larger companies.

Use of proceeds and capital allocation

• Net proceeds intended for research and product development, clinical studies, commercialization, working capital, general corporate purposes, and potential strategic acquisitions.

• Management retains broad discretion over allocation of net proceeds.